Suppliers / SM Biomed Sdn.Bhd

SM Biomed Sdn.Bhd

Malaysia 88 employees Updated 9 July 2026

SM Biomed Sdn.Bhd is an API manufacturer based in Malaysia. It holds 8 active US drug master files. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 28 July 2023 as VAI.

8
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
13
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
4 of 4 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 28 July 2023 VAI US FDA
  • 23 March 2018 VAI US FDA
  • 11 March 2016 VAI US FDA
  • 7 March 2013 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Malaysia, Malaysia 3005983287

What they file, and where

Molecule Regulators Docs
Erythromycin US FDA 8

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
DAV (Vietnam) 13 None
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. SM Biomed Sdn.Bhd comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 28 July 2023.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates